Clinical Commander

Back to dossier
cardio.cardiac-tamponade.chylopericardium.v1PRODUCTION
cardio.cardiac-tamponade.chylopericardium.v1

Cardiac tamponade — chylopericardium (chylous pericardial effusion)

cardiologyacuteadult
Hard-required inputs
0 / 10
Care setting:

Encounter flow

9/12 authored

Canonical 12-phase frame with authored status for this dossier.

Current phase

Frame

Detailed

Chylopericardium — chylous pericardial effusion characterized by milky fluid with TG >500 mg/dL and chylomicrons; primary (idiopathic congenital thoracic-duct anomaly) or secondary (post-cardiothoracic surgery, lymphoma, TB, trauma, LAM, radiation); treatment ladder MCT diet → octreotide → surgical ligation → pericardiectomy (ESC 2015 §Specific Etiologies; Akamatsu Ann Thorac Surg 1994 PMID 8311605)

Inputs
1
Actions
0
Advance rule
Set
Advance when

chylopericardium clinical context confirmed

Patient inputs (10)

Primary idiopathic chylopericardium more common in younger patients; secondary causes (post-surgical, lymphoma, TB) span all ages (Akamatsu PMID 8311605; Yokota 1989)

Compensatory tachycardia in tamponade (ESC 2015)

Etiology drives differential and treatment: post-surgical (thoracic-duct injury), lymphoma (mass infiltration), TB (mediastinal lymphadenopathy), trauma (penetrating injury), idiopathic (congenital), LAM (lymphatic disorder) (Akamatsu PMID 8311605; Imazio JACC 2020)

Renal function for diuretic + drug dosing + contrast for imaging; KDIGO 2026 race-free eGFR (Inker NEJM 2021)

JVD prominent in tamponade (Beck triad); chylous accumulation may be insidious (ESC 2015)

TTE for effusion size + tamponade physiology + RV/RA collapse + IVC plethora (ESC 2015 Class I)

Chest CT/MRI for mediastinal mass (lymphoma), thoracic-duct anatomy, post-surgical anatomy, lymphadenopathy (TB), pleural effusion (chylothorax often co-existent) (Imazio JAMA 2015 PMID 26461998)

Pericardial fluid triglycerides >500 mg/dL diagnostic; pericardial-to-serum TG ratio >1; cholesterol-to-TG ratio <1; chylomicrons on lipoprotein electrophoresis confirm (Akamatsu PMID 8311605)

Pericardial fluid analysis: cytology (lymphoma), gram stain + culture, AFB + Xpert MTB/RIF (TB), cell count + differential (lymphocyte-predominant in chylous), chemistry, ADA (TB) (ESC 2015)

Hypotension is part of Beck triad in tamponade physiology; chylous effusions may accumulate slowly with preserved BP until late (ESC 2015)

* = hard-required. Engine cannot meaningfully run until these are filled.

Severity triggers (5)

5 need judgement
  • informationallife_threateningtamponade_physiology_with_chylous_effusion_emergent_drainage
    Tamponade physiology with chylous pericardial effusion (Beck triad + pulsus paradoxus + RV/RA collapse on echo) — emergent pericardiocentesis mandatory while etiology workup proceeds (ESC 2015 Class I; Akamatsu Ann Thorac Surg 1994 PMID 8311605)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalseverehigh_volume_chyle_output_despite_conservative_management_surgical_indication
    High-volume chyle output >1 L/day persistent despite 4-6 weeks of MCT diet ± octreotide — surgical thoracic-duct ligation indicated (Riquet EJCTS 1996; Chen J Cardiothorac Surg 2014)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalseverelymphoma_confirmed_as_chylopericardium_etiology_oncology_referral_mandatory
    Pericardial fluid cytology + flow cytometry positive for lymphoma OR mediastinal mass biopsy confirms lymphoma — chylopericardium is paraneoplastic; oncology + multidisciplinary tumor board mandatory (Lyon EHJ 2022 PMID 35993161; Imazio JACC 2020 PMID 32919577)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalseveretb_confirmed_as_chylopericardium_etiology_anti_tb_therapy_mandatory
    AFB stain + Xpert MTB/RIF + ADA elevated in pericardial fluid OR mediastinal lymph node biopsy confirms TB — anti-tubercular therapy mandatory + isolation precautions + ID/public health notification (Cherian Indian J Tuberc 2018; ESC 2015)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalsevereconstrictive_pericarditis_developing_post_chylopericardium_pericardiectomy_indication
    Constrictive pericarditis physiology developing during or after chylopericardium recovery — pericardiectomy indicated (rare complication but reported per Akamatsu Ann Thorac Surg 1994 PMID 8311605)
    Trigger could not be auto-evaluated — needs clinician judgement.

Workflow calculators

Run this disease's risk and dosing calculators inline.

RED_FLAGSrequiredDrives risk stratification
Loading…

Recommended regimen

Chylopericardium — pericardiocentesis bridge + conservative MCT diet → octreotide → surgical thoracic-duct ligation + pericardial window (ESC 2015 §Specific Etiologies; Akamatsu Ann Thorac Surg 1994 PMID 8311605; Markham Pediatr Cardiol 2013; Riquet EJCTS 1996)
axis: chylopericardium_conservative_mct_then_octreotide_then_surgical
Selected axis "Chylopericardium — pericardiocentesis bridge + conservative MCT diet → octreotide → surgical thoracic-duct ligation + pericardial window (ESC 2015 §Specific Etiologies; Akamatsu Ann Thorac Surg 1994 PMID 8311605; Markham Pediatr Cardiol 2013; Riquet EJCTS 1996)" by default fallback (first axis)
  • medium_chain_triglyceride_diet
    first line
    nutrition_intervention
    MCT-based formula or oil 1-2 g/kg/day; total dietary fat <5 g/day; supplement fat-soluble vitamins (A, D, E, K) • enteral • continuous nutritional intervention × 4-6 wk
    triggers: confirmed_chylopericardium_post_pericardiocentesis_first_line_conservative
    Akamatsu Ann Thorac Surg 1994 PMID 8311605 — MCTs absorbed directly into portal vein bypassing thoracic duct; reduces chyle production; ~50-70% resolve with diet alone in 4-6 wk
  • total_parenteral_nutrition_TPN
    add on
    nutrition_intervention
    fat-free or MCT-only TPN per nutrition team • IV • continuous TPN
    triggers: mct_diet_alone_ineffective_or_severe_malnutrition
    Bowel rest with TPN further reduces chyle production; for refractory cases or malnutrition (Akamatsu PMID 8311605)
  • octreotide
    second line
    somatostatin_analog
    50 µg SC TID titrate to 100-200 µg SC TID • SC • TID
    triggers: chylopericardium_failing_mct_diet_after_1_2_wk, refractory_chyle_output_despite_dietary_intervention
    Markham Pediatr Cardiol 2013 + adult case series — somatostatin analog reduces splanchnic blood flow + thoracic-duct lymph flow; alternative to surgery; monitor for hyperglycemia + GI side effects + gallstones with prolonged use
    rxcui 7617
  • lanreotide
    second line
    somatostatin_analog_long_acting
    60-120 mg SC monthly • SC • monthly
    triggers: chylopericardium_requiring_long_term_somatostatin_or_octreotide_intolerance
    Long-acting alternative to octreotide for chronic management; once-monthly dosing improves adherence
    rxcui 236167
  • thoracic_duct_ligation_surgical
    rescue
    surgical_intervention
    open thoracotomy or VATS thoracic-duct ligation + pericardial window • surgical • one-time
    triggers: conservative_management_failure_after_4_6_wk, high_volume_chyle_output_persistent, recurrent_chylopericardium_post_drainage
    Riquet EJCTS 1996 + Chen J Cardiothorac Surg 2014 — definitive surgical management; VATS approach minimally invasive; pericardial window prevents recurrence + provides ongoing drainage
  • pericardiectomy
    rescue
    surgical_intervention
    partial or total pericardiectomy • surgical • one-time
    triggers: constrictive_pericarditis_developing_post_chylopericardium, multiple_recurrences_despite_thoracic_duct_ligation
    Definitive for constrictive sequelae; rarely needed in chylopericardium but reported (Akamatsu PMID 8311605)
  • acetaminophen
    first line
    analgesic
    650-1000 mg q6h scheduled • PO • q6h
    triggers: pericarditic_pain
    Preferred analgesic; NSAIDs avoided as inflammatory component minimal in chylopericardium and may not address mechanism
    rxcui 161
  • normal saline
    first line
    isotonic_crystalloid
    500-1000 mL bolus pre-drainage • IV • rapid bolus
    triggers: hypotension_pre_pericardiocentesis_in_tamponade
    Bridge preload (ESC 2015)
    rxcui 9863
  • norepinephrine
    rescue
    vasopressor
    0.05-0.1 µg/kg/min titrate MAP ≥65 • IV • continuous
    triggers: SBP_lt_85_despite_fluids_in_tamponade
    Bridge only — does not address obstruction (Roy JAMA 2007)
    rxcui 7512
  • lymphoma_directed_chemotherapy
    comorbidity specific
    antineoplastic
    per oncology (e.g., R-CHOP for DLBCL, ABVD for Hodgkin) • IV • per regimen
    triggers: lymphoma_confirmed_as_etiology_of_chylopericardium
    Lyon EHJ 2022 PMID 35993161 — treating underlying lymphoma resolves chylopericardium when caused by lymphatic compression/infiltration
  • rifampin_isoniazid_pyrazinamide_ethambutol_RIPE
    comorbidity specific
    antitubercular_combination
    standard 4-drug RIPE × 2 mo intensive then 4 mo continuation • PO • daily
    triggers: tb_confirmed_as_etiology_of_chylopericardium
    CDC/ATS/IDSA TB treatment guidelines + Cherian Indian J Tuberc 2018 — TB lymphadenitis treatment resolves chylous compression
  • warfarin
    comorbidity specific
    vitamin_k_antagonist
    2.5-5 mg PO daily INR target 2-3 • PO • daily
    triggers: subclavian_vein_thrombosis_as_etiology_of_chylopericardium
    Anticoagulation for upper extremity DVT/SVC syndrome causing thoracic-duct outflow obstruction; balance with bleeding risk in pericardial drainage (CHEST 2021 AC guideline)
    rxcui 11289

outpatient playbook — drug actions (4)

  1. 1. transition off MCT diet at 4-6 wk if resolution
    gradual reintroduction of long-chain triglycerides as tolerated • enteral • gradual
    trigger: Confirmed resolution at 4-6 wk
    Akamatsu PMID 8311605
  2. 2. discontinue octreotide/lanreotide if conservative success
    rxcui 40790
    taper and discontinue • SC • taper over 1-2 wk
    trigger: Confirmed resolution
    Avoid prolonged exposure complications
  3. 3. continue lymphoma chemotherapy/TB ATT/AC for thrombosis per specialty
    per regimen • per agent • per regimen
    trigger: Etiology-specific treatment
    Multidisciplinary specialty care
  4. 4. analgesia PRN
    rxcui 161
    acetaminophen 650 mg PRN • PO • PRN
    trigger: Occasional discomfort
    Avoid NSAIDs

Auto-drafted A&P note

outpatient

Subjective

- Possible entry pathways: Pericardial effusion with milky/opalescent fluid on pericardiocentesis aspirate — chylopericardium until proven otherwise (Akamatsu Ann Thorac Surg 1994 PMID 8311605; ESC 2015 §Specific Etiologies); Pericardial fluid triglycerides >500 mg/dL with chylomicrons on lipoprotein electrophoresis (pericardial > serum TG ratio >1) (Akamatsu PMID 8311605; Imazio JAMA 2015 PMID 26461998); Post-cardiothoracic surgery (CABG, transplant, congenital repair) with new pericardial effusion within 30 days — high suspicion for thoracic-duct injury chylopericardium (Kshettry Ann Thorac Surg 1996; Riquet EJCTS 1996).

Objective

- No vitals, labs, or imaging entered for this encounter.

Assessment

**Cardiac tamponade — chylopericardium (chylous pericardial effusion)** (cardio.cardiac-tamponade.chylopericardium.v1).
Phenotype framing: Differentiate: primary idiopathic chylopericardium vs secondary (post-cardiac-surgery thoracic-duct injury — leading modern cause; lymphoma — leading neoplastic cause; TB — endemic regions; trauma; LAM/lymphangiomatosis; radiation; subclavian vein thrombosis); ALSO differentiate from cholesterol pericarditis (high cholesterol, low TG) and pseudo-chylous effusion (high cholesterol crystals, no chylomicrons) (Akamatsu PMID 8311605; Imazio JAMA 2015)
Scope: Chylopericardium — chylous pericardial effusion characterized by milky fluid with TG >500 mg/dL and chylomicrons; primary (idiopathic congenital thoracic-duct anomaly) or secondary (post-cardiothoracic surgery, lymphoma, TB, trauma, LAM, radiation); treatment ladder MCT diet → octreotide → surgical ligation → pericardiectomy (ESC 2015 §Specific Etiologies; Akamatsu Ann Thorac Surg 1994 PMID 8311605)

No severity triggers fired against current inputs.

Plan

Regimen axis: **Chylopericardium — pericardiocentesis bridge + conservative MCT diet → octreotide → surgical thoracic-duct ligation + pericardial window (ESC 2015 §Specific Etiologies; Akamatsu Ann Thorac Surg 1994 PMID 8311605; Markham Pediatr Cardiol 2013; Riquet EJCTS 1996)**.
1. medium_chain_triglyceride_diet MCT-based formula or oil 1-2 g/kg/day; total dietary fat <5 g/day; supplement fat-soluble vitamins (A, D, E, K) enteral continuous nutritional intervention × 4-6 wk (nutrition_intervention, first line) — Akamatsu Ann Thorac Surg 1994 PMID 8311605 — MCTs absorbed directly into portal vein bypassing thoracic duct; reduces chyle production; ~50-70% resolve with diet alone in 4-6 wk
2. total_parenteral_nutrition_TPN fat-free or MCT-only TPN per nutrition team IV continuous TPN (nutrition_intervention, add on) — Bowel rest with TPN further reduces chyle production; for refractory cases or malnutrition (Akamatsu PMID 8311605)
3. octreotide 50 µg SC TID titrate to 100-200 µg SC TID SC TID (somatostatin_analog, second line) — Markham Pediatr Cardiol 2013 + adult case series — somatostatin analog reduces splanchnic blood flow + thoracic-duct lymph flow; alternative to surgery; monitor for hyperglycemia + GI side effects + gallstones with prolonged use
4. lanreotide 60-120 mg SC monthly SC monthly (somatostatin_analog_long_acting, second line) — Long-acting alternative to octreotide for chronic management; once-monthly dosing improves adherence
5. thoracic_duct_ligation_surgical open thoracotomy or VATS thoracic-duct ligation + pericardial window surgical one-time (surgical_intervention, rescue) — Riquet EJCTS 1996 + Chen J Cardiothorac Surg 2014 — definitive surgical management; VATS approach minimally invasive; pericardial window prevents recurrence + provides ongoing drainage
6. pericardiectomy partial or total pericardiectomy surgical one-time (surgical_intervention, rescue) — Definitive for constrictive sequelae; rarely needed in chylopericardium but reported (Akamatsu PMID 8311605)
7. acetaminophen 650-1000 mg q6h scheduled PO q6h (analgesic, first line) — Preferred analgesic; NSAIDs avoided as inflammatory component minimal in chylopericardium and may not address mechanism
8. normal saline 500-1000 mL bolus pre-drainage IV rapid bolus (isotonic_crystalloid, first line) — Bridge preload (ESC 2015)
9. norepinephrine 0.05-0.1 µg/kg/min titrate MAP ≥65 IV continuous (vasopressor, rescue) — Bridge only — does not address obstruction (Roy JAMA 2007)
10. lymphoma_directed_chemotherapy per oncology (e.g., R-CHOP for DLBCL, ABVD for Hodgkin) IV per regimen (antineoplastic, comorbidity specific) — Lyon EHJ 2022 PMID 35993161 — treating underlying lymphoma resolves chylopericardium when caused by lymphatic compression/infiltration
11. rifampin_isoniazid_pyrazinamide_ethambutol_RIPE standard 4-drug RIPE × 2 mo intensive then 4 mo continuation PO daily (antitubercular_combination, comorbidity specific) — CDC/ATS/IDSA TB treatment guidelines + Cherian Indian J Tuberc 2018 — TB lymphadenitis treatment resolves chylous compression
12. warfarin 2.5-5 mg PO daily INR target 2-3 PO daily (vitamin_k_antagonist, comorbidity specific) — Anticoagulation for upper extremity DVT/SVC syndrome causing thoracic-duct outflow obstruction; balance with bleeding risk in pericardial drainage (CHEST 2021 AC guideline)

Setting playbook (outpatient) — Long-term resolution surveillance (echo + symptoms); recurrence prevention; MCT diet maintenance/discontinuation; constriction surveillance; etiology-specific surveillance (lymphoma remission, TB cure, post-surgical recovery) (ESC 2015; Akamatsu PMID 8311605; Lyon EHJ 2022)
13. transition off MCT diet at 4-6 wk if resolution gradual reintroduction of long-chain triglycerides as tolerated enteral gradual — Confirmed resolution at 4-6 wk (Akamatsu PMID 8311605)
14. discontinue octreotide/lanreotide if conservative success taper and discontinue SC taper over 1-2 wk — Confirmed resolution (Avoid prolonged exposure complications)
15. continue lymphoma chemotherapy/TB ATT/AC for thrombosis per specialty per regimen per agent per regimen — Etiology-specific treatment (Multidisciplinary specialty care)
16. analgesia PRN acetaminophen 650 mg PRN PO PRN — Occasional discomfort (Avoid NSAIDs)

Non-pharmacologic actions:
- Cardiology follow-up at 6 mo + 12 mo then annually × 2 yr
- Cardiothoracic surgery follow-up post-pericardiectomy or thoracic-duct ligation per surgical schedule
- Oncology surveillance per cancer protocol
- ID surveillance per TB treatment protocol
- Nutrition follow-up if MCT diet ongoing
- Activity progression per recovery
- Vaccination updates (pneumococcal, influenza, COVID-19)

AVOID / contraindication checks:
- Positive_pressure_ventilation_AVOID_pre_drain_in_tamponade (ESC 2015)
- Long_chain_triglyceride_diet_CONTRAINDICATED_increases_chyle_production_use_MCT_only (Akamatsu PMID 8311605)
- Nsaid_minimal_role_in_chylopericardium_no_inflammatory_component (Imazio JAMA 2015 PMID 26461998)
- Colchicine_minimal_role_in_chylopericardium_no_inflammatory_component (ICAP PMID 23992557)
- Octreotide_monitor_hyperglycemia_diabetic_patients_dose_adjustment (drug label)
- Octreotide_prolonged_use_gallstone_risk_monitor_with_ultrasound_q6mo (drug label)
- Tpn_central_line_associated_blood_stream_infection_risk_strict_aseptic_technique (CDC guidelines)
- Tpn_metabolic_complications_hyperglycemia_electrolyte_imbalance_monitor_daily (ASPEN guidelines)
- Thoracic_duct_ligation_pre_op_lymphangiography_recommended_for_anatomy_definition (Riquet EJCTS 1996)
- Pericardiectomy_in_chylous_effusions_rare_indication_reserve_for_constrictive_sequelae (Akamatsu PMID 8311605)
- Warfarin_balance_anticoagulation_with_bleeding_risk_pericardial_drainage_consider_LMWH_bridge (CHEST 2021)

Monitoring

Regimen monitoring:
- echo during active treatment q12 24h initial then weekly (ESC 2015)
- pericardial drainage output q1h initial then q4h (Akamatsu PMID 8311605)
- weekly albumin prealbumin lymphocyte count for nutritional status on mct diet (ASPEN guidelines)
- weekly lipid panel fat soluble vitamins A D E K (ASPEN)
- daily BMP LFTs on TPN (ASPEN)
- glucose q6h on octreotide or TPN (drug label)
- long term echo at 1 3 6 12 mo for constriction surveillance (Akamatsu PMID 8311605)
- gallbladder ultrasound q6mo on prolonged octreotide (drug label)
- CBC BMP creatinine during octreotide or chemotherapy or anti TB (per regimen)

Setting (outpatient) monitoring:
- Echo at 6 mo + 12 mo then annually × 2 yr
- CBC + BMP + LFTs + lipid panel per regimen
- Etiology-specific surveillance per specialty

Monitoring phase: Re-accumulation surveillance (echo q12-24h initially then weekly during conservative management); pericardial fluid output if drain in place (target <50 mL/24h × 24h before removal); nutritional adequacy on MCT diet (weekly weight, albumin, prealbumin, lymphocyte count); long-term constriction surveillance post-recovery (echo at 1, 3, 6, 12 mo)

Disposition

Current setting: outpatient — Long-term resolution surveillance (echo + symptoms); recurrence prevention; MCT diet maintenance/discontinuation; constriction surveillance; etiology-specific surveillance (lymphoma remission, TB cure, post-surgical recovery) (ESC 2015; Akamatsu PMID 8311605; Lyon EHJ 2022)

Disposition criteria:
- Stable + chylopericardium resolved + multidisciplinary follow-up ongoing → routine annual cardiology follow-up

Escalation triggers (move to higher acuity):
- Recurrent chylopericardium → repeat workup + consider surgical thoracic-duct ligation
- Constriction development → cardiothoracic surgery for pericardiectomy
- New oncology findings → multidisciplinary reassessment
- TB recurrence/MDR-TB → ID specialist + extended therapy
- Tamponade recurrence → re-route to acute pathway

Earlier-Return Triggers

Return-precaution thresholds (watch for):
- [LIFE_THREATENING] Tamponade physiology with chylous pericardial effusion (Beck triad + pulsus paradoxus + RV/RA collapse on echo) — emergent pericardiocentesis mandatory while etiology workup proceeds (ESC 2015 Class I; Akamatsu Ann Thorac Surg 1994 PMID 8311605)
- [SEVERE] High-volume chyle output >1 L/day persistent despite 4-6 weeks of MCT diet ± octreotide — surgical thoracic-duct ligation indicated (Riquet EJCTS 1996; Chen J Cardiothorac Surg 2014)
- [SEVERE] Pericardial fluid cytology + flow cytometry positive for lymphoma OR mediastinal mass biopsy confirms lymphoma — chylopericardium is paraneoplastic; oncology + multidisciplinary tumor board mandatory (Lyon EHJ 2022 PMID 35993161; Imazio JACC 2020 PMID 32919577)

Citations

- 2015 ESC Guidelines for the diagnosis and management of pericardial diseases (Adler EHJ 2015 PMID 26320112) §Specific Etiologies — primary; Akamatsu Ann Thorac Surg 1994 PMID 8311605 anchors classification + management algorithm; Riquet EJCTS 1996 + Chen J Cardiothorac Surg 2014 anchor surgical thoracic-duct ligation; Markham Pediatr Cardiol 2013 anchors octreotide therapy; Kshettry Ann Thorac Surg 1996 anchors post-cardiac-surgery etiology; Imazio JACC 2020 PMID 32919577 + Lyon EHJ 2022 PMID 35993161 anchor neoplastic overlap; Cherian Indian J Tuberc 2018 anchors TB-related chylopericardium; CDC/ATS/IDSA TB guidelines for ATT regimen; Imazio JAMA 2015 PMID 26461998 anchors pericardial disease diagnosis + management overview. [PMID:26320112](https://pubmed.ncbi.nlm.nih.gov/26320112/)
- Cited evidence (PMID 8311605) [PMID:8311605](https://pubmed.ncbi.nlm.nih.gov/8311605/)
- Cited evidence (PMID 26461998) [PMID:26461998](https://pubmed.ncbi.nlm.nih.gov/26461998/)
- Cited evidence (PMID 32919577) [PMID:32919577](https://pubmed.ncbi.nlm.nih.gov/32919577/)
- Cited evidence (PMID 35993161) [PMID:35993161](https://pubmed.ncbi.nlm.nih.gov/35993161/)

Last reconciled with current guidelines: 2026-05-15.
References
  • 2015 ESC Guidelines for the diagnosis and management of pericardial diseases (Adler EHJ 2015 PMID 26320112) §Specific Etiologies — primary; Akamatsu Ann Thorac Surg 1994 PMID 8311605 anchors classification + management algorithm; Riquet EJCTS 1996 + Chen J Cardiothorac Surg 2014 anchor surgical thoracic-duct ligation; Markham Pediatr Cardiol 2013 anchors octreotide therapy; Kshettry Ann Thorac Surg 1996 anchors post-cardiac-surgery etiology; Imazio JACC 2020 PMID 32919577 + Lyon EHJ 2022 PMID 35993161 anchor neoplastic overlap; Cherian Indian J Tuberc 2018 anchors TB-related chylopericardium; CDC/ATS/IDSA TB guidelines for ATT regimen; Imazio JAMA 2015 PMID 26461998 anchors pericardial disease diagnosis + management overview. — PMID:26320112
  • Cited evidence (PMID 8311605) — PMID:8311605
  • Cited evidence (PMID 26461998) — PMID:26461998
  • Cited evidence (PMID 32919577) — PMID:32919577
  • Cited evidence (PMID 35993161) — PMID:35993161